Drug Profile
LMB 9
Alternative Names: B3ds(Fv)-PE38; NSC 691236Latest Information Update: 27 Jan 2006
Price :
$50
*
At a glance
- Originator Battelle Memorial Institute; National Cancer Institute (USA)
- Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 27 Jan 2006 IVAX Corporation has been acquired by Teva Pharmaceutical Industries
- 23 Oct 2003 Phase-I clinical trials in Colorectal cancer in USA (IV-infusion)
- 23 Oct 2003 Phase-I clinical trials in Gastrointestinal cancer in USA (IV-infusion)